KR20170066432A - 정신병적 장애를 치료하기 위한 방법 및 조성물 - Google Patents

정신병적 장애를 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20170066432A
KR20170066432A KR1020177010114A KR20177010114A KR20170066432A KR 20170066432 A KR20170066432 A KR 20170066432A KR 1020177010114 A KR1020177010114 A KR 1020177010114A KR 20177010114 A KR20177010114 A KR 20177010114A KR 20170066432 A KR20170066432 A KR 20170066432A
Authority
KR
South Korea
Prior art keywords
glutathione
disorder
nvhl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177010114A
Other languages
English (en)
Korean (ko)
Inventor
조나단 킬
Original Assignee
사운드 파마슈티칼스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사운드 파마슈티칼스 인코퍼레이티드 filed Critical 사운드 파마슈티칼스 인코퍼레이티드
Priority to KR1020237022184A priority Critical patent/KR20230107890A/ko
Publication of KR20170066432A publication Critical patent/KR20170066432A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177010114A 2014-09-15 2015-09-15 정신병적 장애를 치료하기 위한 방법 및 조성물 Ceased KR20170066432A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237022184A KR20230107890A (ko) 2014-09-15 2015-09-15 정신병적 장애를 치료하기 위한 방법 및 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050635P 2014-09-15 2014-09-15
US62/050,635 2014-09-15
PCT/US2015/050255 WO2016044314A1 (en) 2014-09-15 2015-09-15 Methods and compositions for treating psychotic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022184A Division KR20230107890A (ko) 2014-09-15 2015-09-15 정신병적 장애를 치료하기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20170066432A true KR20170066432A (ko) 2017-06-14

Family

ID=55533760

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177010114A Ceased KR20170066432A (ko) 2014-09-15 2015-09-15 정신병적 장애를 치료하기 위한 방법 및 조성물
KR1020237022184A Ceased KR20230107890A (ko) 2014-09-15 2015-09-15 정신병적 장애를 치료하기 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237022184A Ceased KR20230107890A (ko) 2014-09-15 2015-09-15 정신병적 장애를 치료하기 위한 방법 및 조성물

Country Status (8)

Country Link
US (3) US20170246148A1 (https=)
EP (1) EP3194027B1 (https=)
JP (3) JP2017534673A (https=)
KR (2) KR20170066432A (https=)
AU (4) AU2015317877A1 (https=)
CA (1) CA2961380A1 (https=)
ES (1) ES3062284T3 (https=)
WO (1) WO2016044314A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884632B (zh) * 2012-12-27 2018-01-02 索尼公司 细胞分析系统及细胞分析方法
CN105683355B (zh) 2013-11-08 2018-07-06 索尼公司 细胞分析系统、细胞分析程序和细胞分析方法
HRP20241559T1 (hr) * 2016-05-18 2025-02-14 Sound Pharmaceuticals Incorporated Ebselen za uporabu u liječenju menierove bolesti
CN107362144B (zh) * 2017-08-03 2020-04-17 华侨大学 一种鲁拉西酮脑靶向脂质体注射剂及其制备方法
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
MX2020004975A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.
KR102927722B1 (ko) * 2020-05-09 2026-02-19 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
US20250128055A1 (en) * 2021-10-08 2025-04-24 Albert Ludwigs Universität Freiburg Treatment of psychiatric disorders with deep brain stimulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957901B1 (en) * 1996-12-31 2009-11-18 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US20050032708A1 (en) * 2001-09-27 2005-02-10 Bush Ashley I. Modulation of physiological processes and agents useful for same
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
EP2736890A4 (en) * 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS

Also Published As

Publication number Publication date
US20210379017A1 (en) 2021-12-09
US20170246148A1 (en) 2017-08-31
EP3194027A1 (en) 2017-07-26
WO2016044314A1 (en) 2016-03-24
JP2021181473A (ja) 2021-11-25
EP3194027B1 (en) 2026-02-11
ES3062284T3 (en) 2026-04-09
US20240050409A1 (en) 2024-02-15
EP3194027A4 (en) 2018-04-18
JP2017534673A (ja) 2017-11-24
JP2023169413A (ja) 2023-11-29
AU2023200727A1 (en) 2023-03-09
CA2961380A1 (en) 2016-03-24
AU2025201645A1 (en) 2025-03-27
AU2021200583A1 (en) 2021-03-04
KR20230107890A (ko) 2023-07-18
EP3194027C0 (en) 2026-02-11
AU2015317877A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
US20240050409A1 (en) Methods and Compositions for Treating Psychotic Disorders
US20250032459A1 (en) Method for treating neurodegenerative diseases
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
Wu et al. Acrolein aggravates secondary brain injury after intracerebral hemorrhage through Drp1-mediated mitochondrial oxidative damage in mice
TW202131910A (zh) 使用mtorc1調節劑的治療方法
Kim et al. Neuroprotective effects of a protein tyrosine phosphatase inhibitor against hippocampal excitotoxic injury
US20070054886A1 (en) Ras antagonists for treating neurodegenerative disorders
Nakazawa et al. Oral consumption of α-glucosyl-hesperidin could prevent lens hardening, which causes presbyopia
US20230052152A1 (en) Compounds for treatment of alzheimer's disease
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
CN114028376A (zh) Mg在制备高尿酸血症肾病和/或痛风性关节炎的nlrp3通路抑制剂中的应用
JP2008502607A (ja) 痴呆の予防および治療におけるＬ−ｎ−ブチルフタリドの適用
TWI781073B (zh) 正丁烯基苯酞的醫藥用途
RU2506950C2 (ru) Комбинация карбостирила и карнитина
US20230333087A1 (en) Methods for monitoring patient response to treatment of retinal oxidative diseases
JP5714524B2 (ja) 痴呆の予防および治療におけるＬ−ｎ−ブチルフタリドの適用
EP3478279A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
Falah The role of the cdk5 pathway and NMDA receptor phosphorylation in neurodegeneration in hippocampal sclerosis
Sagona Optical imaging and automated behavior as tools for the diagnostic monitoring of brain function in neurodevelopmental disorders
WO2025186837A1 (en) A synergistic bioactive composition for controlling neuromuscular pain and repairing nerve damage
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物
EA048112B1 (ru) Соединения для лечения болезни альцгеймера
OA21243A (en) Compounds for treatment of alzheimer's disease.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170413

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200915

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211201

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220801

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220801

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220531

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200915

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230201

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230102

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220801

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220531

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211201

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200915

X601 Decision of rejection after re-examination